Kardiogen Genetic Risk Assessment: The New Blueprint for Heart Health
At a Glance
- Sample Required: Blood (EDTA)
- Fasting Rules: Not required
- Turnaround Time (TAT): 10–14 days
- Base Cost: [Insert Current 2026 Price]
Coronary Artery Disease (CAD) remains the leading cause of mortality worldwide, with South Asians facing a 40% higher associated death rate compared to other ethnicities. While traditional risk factors like cholesterol and blood pressure are routinely measured, they only capture a snapshot of current health. The Kardiogen Polygenic Risk Score (PRS) test by DNA Labs India goes deeper—it maps your inherited genetic susceptibility to CAD, offering a lifelong risk blueprint that empowers proactive prevention.
Understanding Polygenic Risk Scores (PRS)
Most chronic diseases, including CAD, are polygenic—meaning they arise from the cumulative effect of many genetic variants, each contributing a small amount of risk. A PRS aggregates these variants into a single score that quantifies your genetic predisposition relative to a reference population. Unlike monogenic disorders caused by a single gene mutation, PRS captures the complex interplay of thousands of common variants.
DNA Labs India utilizes Next-Generation Sequencing (NGS) and Whole Exome Sequencing (WES) to analyze over 1.29 million genetic markers, ensuring comprehensive coverage of known CAD-associated loci. This approach replaces outdated Sanger sequencing, which is impractical for large-scale variant analysis.
The Kardiogen CAD-PRS Test: Methodology and Accuracy
The Kardiogen test is a genome-wide screening tool that evaluates your genetic risk for CAD. It is performed on a simple blood sample (EDTA), from which DNA is extracted and subjected to high-throughput NGS. The resulting data is processed through a validated algorithm that calculates your PRS.
Critically, the model has been explicitly validated for the South Asian population. Most global PRS models are built on European DNA databases, leading to inaccurate predictions for other ethnicities. DNA Labs India's validation ensures that the risk estimates are clinically meaningful for Indian patients, addressing a significant gap in preventive cardiology.
Clinical Utility and Interpretation
A high PRS indicates a statistically elevated risk of developing CAD compared to the general population. It is not a diagnosis but a risk stratification tool. Evidence shows that lifestyle modifications—such as diet, exercise, and targeted pharmacotherapy (e.g., statins)—can substantially mitigate this inherited risk. Early identification allows for decades of proactive intervention, making this test particularly valuable for young adults.
Key Insight: A high PRS is not a verdict—it's a call to action. With appropriate management, you can rewrite your cardiac future.
Traditional Lipid Panel vs. Kardiogen PRS
| Feature | Traditional Lipid Panel | Kardiogen PRS |
|---|---|---|
| What it measures | Current cholesterol levels (LDL, HDL, triglycerides) | Inherited genetic risk for CAD (1.29M markers) |
| Temporal scope | Snapshot of present health | Lifelong baseline risk |
| Sample type | Blood (serum or plasma) | Blood (EDTA) |
| Fasting required | Yes (usually 9–12 hours) | No |
| Turnaround time | 24–48 hours | 10–14 days |
| Clinical action | Guides immediate lipid-lowering therapy | Informs long-term prevention strategy |
Who Should Consider This Test?
- Individuals with a family history of premature CAD or heart attacks.
- Adults of South Asian descent, given the elevated baseline risk.
- Those with borderline risk factors who need additional stratification.
- Young adults seeking early prevention guidance.
- Patients with unexplained elevated cholesterol not fully explained by lifestyle.
Test Procedure and Sample Requirements
The test requires a standard blood draw into an EDTA tube. No fasting is necessary. The sample is processed at our ISO 9001 certified laboratory using NGS-based genotyping. Results are typically available within 10–14 business days and are accompanied by a detailed clinical report that includes your PRS percentile and actionable recommendations.
Why South Asian Validation Matters
Genetic risk models are population-specific. A PRS derived from European cohorts may misclassify risk in South Asians due to differing allele frequencies and linkage disequilibrium patterns. DNA Labs India has invested in validating the Kardiogen model specifically for the Indian population, ensuring that your score is calibrated to your genetic heritage. This is a critical step toward precision medicine in India.
Limitations and Ethical Considerations
While PRS provides powerful risk information, it does not account for all genetic influences or environmental factors. A high score does not guarantee disease, and a low score does not eliminate risk. The test is intended for risk stratification, not diagnosis. Genetic counseling is recommended to help interpret results in the context of your overall health.
Frequently Asked Questions
What is the difference between a traditional lipid panel and the Kardiogen PRS test?
A traditional lipid panel measures current cholesterol levels, providing a snapshot of present health. In contrast, the Kardiogen test maps your lifelong, inherited genetic risk for CAD by analyzing over 1.29 million genetic markers. It tells you your baseline risk before cholesterol levels even begin to rise.
Is the Kardiogen test suitable for all age groups?
Yes. Because your DNA does not change over your lifetime, the test can be taken at any age. Early testing is highly recommended, as discovering a high genetic risk early in life allows for decades of proactive lifestyle choices and medical interventions.
Does a high Kardiogen risk score mean I will definitely get a heart attack?
No. A high score simply indicates a higher statistical probability of developing CAD compared to the general population. It is a predictive risk factor, not a clinical diagnosis. Evidence shows that modifying lifestyle factors—such as diet, exercise, and targeted medications like statins—can significantly neutralize this inherited genetic risk.
Why is South Asian validation important for this genetic test?
Historically, most global genetic models have been built using European DNA databases, which can lead to inaccurate risk predictions for other ethnicities. People of South Asian ancestry have unique genetic profiles and face a 40% higher CAD-associated mortality rate globally. DNA Labs India explicitly validated the Kardiogen model for the South Asian population to ensure unmatched clinical accuracy for Indian patients.
How is the test performed?
The Kardiogen CAD-PRS assessment is exceptionally simple and non-invasive. It requires only a standard blood draw (EDTA sample), which is then sent to our advanced genomic sequencing labs for multi-marker analysis.
Written by: DNA Labs India Scientific Communications Team
Medically Reviewed by: Dr. A. Sharma, MD, Medical Geneticist
Last Updated: July 28, 2026